72,234 articles
Clive Svendsen
Clive N. Svendsen is a British-born stem cell researcher and Executive Director of the Regenerative Medicine Institute at Cedars-Sinai in Los Angeles, studying ALS and Parkinson's disease.
Clive Wood
Clive R. Wood is a British-trained immunologist credited with discovering the PD-1: PD-L1/PD-L2 cancer immunotherapy pathway, who led discovery research at Boehringer Ingelheim before joining OrbiMed in 2025.
Clivia
Clivia, also called bush lily, is a genus of six evergreen flowering plant species in the Amaryllis family, native to South Africa and Eswatini and widely grown as houseplants.
CLL/SLL: relationship between chronic lymphocytic leukemia and small lymphocytic lymphoma
CLL and SLL are the same B-cell cancer, differing only in whether the malignant cells accumulate in the blood (CLL) or in lymph nodes (SLL).
Cln-081
CLN-081 (zipalertinib, TAS6417) is an oral, irreversible, EGFR ex20ins-selective tyrosine kinase inhibitor for NSCLC; REZILIENT1 showed 35.2% ORR, and FDA NDA review has a February 27, 2027 PDUFA date.
CLN1 disease
CLN1 disease (infantile neuronal ceroid lipofuscinosis, Santavuori-Haltia disease, infantile Batten disease) is an autosomal recessive lysosomal storage disorder from PPT1 deficiency, causing psychomotor regression, seizures, blindness by age 2, and early death; later-onset variants exist.
CLN10 disease
CLN10 disease (neuronal ceroid lipofuscinosis type 10, cathepsin D deficiency) is a rare autosomal recessive lysosomal storage disorder caused by CTSD mutations; the congenital form is the most severe NCL, with microcephaly, seizures, and death within hours to weeks of birth.
CLN11 disease
CLN11 disease (neuronal ceroid lipofuscinosis 11, NCL11) is a rare autosomal recessive Batten disease spectrum disorder caused by biallelic GRN mutations, causing seizures, retinitis pigmentosa, ataxia, and cognitive decline from about age 13 to 25; single-copy GRN carriers risk frontotemporal dementia instead.
CLN12 disease
CLN12 disease, also called ATP13A2-related juvenile neuronal ceroid lipofuscinosis or NCL12, is a rare autosomal recessive lysosomal storage disorder from ATP13A2 mutations, causing juvenile-onset ataxia, myoclonus, parkinsonism and cognitive decline, distinct from Kufor-Rakeb syndrome and SPG78.
CLN13 disease
CLN13 disease (Kufs disease type B, NCL13) is a rare autosomal recessive adult-onset neuronal ceroid lipofuscinosis caused by CTSF mutations, producing cathepsin F deficiency, dementia, and movement disturbances without vision loss.
CLN2 disease
CLN2 disease (neuronal ceroid lipofuscinosis type 2, NCL2) is an autosomal recessive lysosomal storage disorder from TPP1 deficiency, causing seizures, motor-language loss and blindness from ages 2-4; treated with intraventricular cerliponase alfa (Brineura).
CLN3
CLN3 (battenin, HGNC:2074) is a chromosome 16p12.1 gene encoding a lysosomal transmembrane protein; mutations cause juvenile Batten disease (CLN3 disease), with childhood vision loss, dementia, epilepsy, and death typically by age 20-30.
CLN3 disease
CLN3 disease (juvenile neuronal ceroid lipofuscinosis, juvenile Batten disease) is an autosomal recessive lysosomal storage disorder from CLN3 gene mutations, causing childhood vision loss, seizures, cognitive decline, and death typically at 20–30 years.
CLN4 disease
CLN4 disease (Parry disease, adult neuronal ceroid lipofuscinosis, NCL4) is a rare autosomal dominant adult-onset NCL caused by DNAJC5 mutations, causing seizures, myoclonus, dementia, and ataxia without vision loss.
CLN5 disease
CLN5 disease is a rare inherited neurodegenerative disorder of the Batten disease group, caused by CLN5 gene mutations and marked by seizures, ataxia, and vision loss.
CLN6 disease
CLN6 disease (NCL6, neuronal ceroid lipofuscinosis type 6) is a rare autosomal recessive Batten disease caused by CLN6 gene mutations, with late infantile, juvenile, and adult-onset forms involving regression, seizures, and ataxia.
CLN7 disease
CLN7 disease (NCL7, neuronal ceroid lipofuscinosis type 7) is a rare autosomal recessive Batten disease variant caused by MFSD8 mutations, beginning at ages 2-7 with seizures, myoclonus, vision loss, and motor and cognitive decline; no approved cure exists.
CLN8 disease
CLN8 disease (Northern epilepsy, EPMR; OMIM 600143) is an autosomal recessive neuronal ceroid lipofuscinosis caused by CLN8 gene mutations, with a milder Finnish epilepsy form and a severe late-infantile form with vision loss.
Cloaca
Cloaca: the single posterior cavity (vent) receiving digestive, urinary, and reproductive tracts in birds, reptiles, amphibians, many fishes, and monotremes; in other mammals it is embryonically septated into rectum and urogenital sinus.
Clobazam
Clobazam (Frisium, Urbanyl, Onfi) is a 1,5-benzodiazepine antiseizure drug approved in the US in 2011 as add-on therapy for Lennox-Gastaut syndrome seizures, dosed by weight, metabolized via CYP2C19, and DEA Schedule IV.
Clobetasol propionate
Clobetasol propionate (Temovate, Clobex) is a super-high potency topical corticosteroid, 0.05% strength, first described 1974, FDA-approved 1985, used for psoriasis and corticosteroid-responsive dermatoses with 2-week, 50 g/week limits.
Clobutinol
Clobutinol (Silomat) is a non-opioid, centrally acting cough suppressant marketed from 1961 and withdrawn in 2007 after a study showed QT prolongation and arrhythmia risk; Brazil's Anvisa suspended it in April 2026.
Clock drawing test
The clock drawing test is a neuropsychological screen in which a person draws a clock set to ten after eleven, probing planning, memory, and visuospatial function.
Clodagh O'Shea
Clodagh O'Shea is an Irish molecular biologist, a professor at the Salk Institute in La Jolla, California, known for research on oncolytic adenoviruses engineered to kill cancer cells.
Clodinafop
Clodinafop (clodinafop-propargyl, Topik, Discover) is an aryloxyphenoxypropionate ACCase-inhibiting post-emergence herbicide for grass weeds in wheat, rye, and triticale, launched in 1991 with the safener cloquintocet-mexyl; EU approval expires 31 July 2027.
Clodronate
Clodronate, also known as clodronic acid, is a first-generation bisphosphonate drug that inhibits bone resorption, used since the 1970s for osteoporosis, Paget's disease, and bone metastases.
Clofarabine
Clofarabine (Clolar, Evoltra, CAFdA) is a second-generation purine nucleoside analog chemotherapy approved in 2004 for relapsed/refractory pediatric ALL; it inhibits ribonucleotide reductase and DNA polymerase after dCK phosphorylation.
Clofazimine
Clofazimine is a lipophilic riminophenazine antibiotic drug, first synthesized in Ireland in 1954, best known as one of three drugs in WHO multidrug therapy for leprosy and later repurposed for drug-resistant tuberculosis and nontuberculous mycobacterial infections.
Clofencet
Clofencet (Genesis, CAS 82691-71-0) is a Monsanto chemical hybridizing agent registered in 1997 to produce hybrid wheat by suppressing pollen in female plants; distinct from the acaricide clofentezine.
Clofentezine
Clofentezine (CAS 74115-24-5), a tetrazine acaricide and IRAC group 10A mite growth inhibitor acting on CHS1, used as a contact ovicide against spider mites; EU approval not renewed by Regulation (EU) 2023/2456 as an endocrine disruptor.